Valuation: Mabvax Therapeutics Holdings Inc

Market Cap 1.11M 971K 896K 825K 1.56M 107M 1.59M 10.7M 4.21M 52.38M 4.17M 4.08M 180M P/E 2016
-0.93x
P/E 2017 -0.25x
Enterprise Value 3.59M 3.14M 2.9M 2.67M 5.03M 346M 5.14M 34.62M 13.62M 169M 13.49M 13.19M 583M EV / Sales 2016
147x
EV / Sales 2017 -
Free-Float
92.02%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.74%-6.36%+3.93%+423.00% 23.29B
-0.14%-0.21%-17.78%-14.84% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
-0.29%-1.50%+24.02%+189.99% 14B
Average -2.85%-1.26%+43.88%+185.29% 26.72B
Weighted average by Cap. -2.96%-2.20%+43.23%+144.89%

Financials

2016 2017
Net sales 148K 129K 119K 110K 207K 14.26M 212K 1.43M 561K 6.98M 556K 544K 24.04M -
Net income -17.66M -15.43M -14.24M -13.13M -24.74M -1.7B -25.29M -170M -66.95M -833M -66.32M -64.87M -2.87B -19.02M -16.62M -15.34M -14.14M -26.65M -1.83B -27.24M -183M -72.11M -897M -71.43M -69.86M -3.09B
Net Debt 470K 411K 379K 349K 659K 45.27M 673K 4.53M 1.78M 22.17M 1.77M 1.73M 76.33M 2.48M 2.17M 2M 1.84M 3.48M 239M 3.55M 23.92M 9.41M 117M 9.32M 9.11M 403M
Logo Mabvax Therapeutics Holdings Inc
MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.
Employees
-